$EVMN News

Evommune (EVMN) Price Target Decreased by 10.03% to 28.22

Needham Initiates Coverage of Evommune (EVMN) with Buy Recommendation

Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28

RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune (EVMN) Price Target Decreased by 21.82% to 31.36

HC Wainwright & Co. Reiterates Neutral on Evommune

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune (EVMN) Price Target Decreased by 24.84% to 40.12

HC Wainwright & Co. Downgrades Evommune (EVMN)

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26

HC Wainwright & Co. Downgrades Evommune to Neutral

William Blair Downgrades Evommune (EVMN)

Evommune terminates oral drug’s development in CSU

Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)

William Blair Downgrades Evommune to Market Perform

Evommune's Skin Disorder Study Falls Short

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria